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ABSTRACT:
Introduction: The annual global incidence of Guillain-Barre Syndrome  is approximately 1–2 per 100,000 person-years. 
Data on Guillain-Barre Syndrome  is very rare from Pakistan, we conducted a retrospective study to assess the clinical 
presentation, and treatment response of these patients. 
METHODOLOGY: 
A retrospective observational study was conducted at the Neurology Department, Pakistan Institute of Medical 
Sciences. A total of 45 patients medical record was reviewed and noted. Administrative permission from head of the 
Department was taken for using the medical record and study was approved by the hospital ethics committee. 
Diagnosis was made on the basis of clinical signs and symptoms and the specific laboratory investigations i.e. lumbar 
puncture for CSF investigation, electromyography and nerve conduction study. Data analysis was conducted in SPSS 
software. 
RESULTS: 
Mean age was 38.7 years, with majority 40 years. Females were predominant 31 (68.9%). Most of the patients had 
AIDP 25 (55.6%) and AMAN 14 (31.1%) variants. There were 25 (55.6%) patients with preceding infections i.e. 
gastrointestinal tract and upper respiratory tract infection. Most patients presented in Autumn 18 (40.0%) and 
Summer seasons 14 (31.1%).  Plasma exchange treatment was done in 37 (82%), whereas 7 (15.8%) were managed 
by IV Ig treatment. After treatment fatigue 33(73.2%), and pain 25(55.5%) were frequent symptoms. Majority had 
improved functional status after treatment, However, 6 (13.3%) patients were able to walk only with help and 5 
(11.1%) were bedridden. None of them died. The mean disability rating index was 50.1 ± 15.4. 
Conclusion: In conclusion, overall, outcome of Guillain-Barre Syndrome patient is favorable, although fatigue and pain 
remain  the common complaints in sequela. It has affected predominantly female population and most patients were 
below 40 years of age. Almost one fourth cases had no response to therapy and these patients were bedridden or 
unable to walk without help.
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INTRODUCTION:
Guillain–Barré syndrome (GBS) is less common, but a 
fatal, immune- mediated disease of the peripheral 
nervous system and the nerve roots.1The primary 
etiology is mostly infection triggered.2 The annual global 
incidence of GBS is approximately 1–2 per 100,000 
person- years. Data suggests that it occurs more 
frequently in males and there is a gradual increase in 
incidence with age, however, it can affect any age 
group.3 
Clinically the patients with GBS usually have weakness 
and sensory signs in the legs that progresses to the 
arms and cranial nerves, although the clinical 
presentation of the disease is heterogeneous and 
several distinct clinical variants exist. About 30% GBS 
leads to intensive care ventilator dependent due to 
respiratory muscle weakness, with subsequent 
increase risk of death.4 The major clinical manifestation 
is weakness, mainly symmetrical, that evolves with 
O R I G I N A L  A R T I C L E
2 4P A K I S T A N  J O U R N A L  O F  N E U R O L O G I C A L  S C I E N C E S V O L .  1 5  ( 4 )  O C T O B E R - D E C E M B E R  2 0 2 0
Sana Younus1, Aisha S Chachar2, Ayesha I Mian3 
time. The average period from onset to Nadir of illness 
is 8 days.5 
The overall duration of GBS is < 12 weeks in routine 
and most of the patients are expected to have 
complete remission in the severity of illness.6 
Approximately mortality occurs in 10% of GBS patients, 
usually from respiratory failure, cardiac arrhythmia, or 
pulmonary embolism, and 20% are left with deficits in 
ambulation or respiration one year later.7 
In the US, GBS is a significant contributor to new 
long-term disability for at least 1,000 persons per year 
and many more elsewhere. Between 25,000 to 
50,000, persons are experiencing at least some 
residual effects from GBS. However, younger patient 
has better prognosis with relatively less residual 
sequele.8
Though the primary immunotherapy with either plasma 
exchange (PE) or immunoglobulin (IVIg) is one of the 
cornerstone of the treatment.9,10 At current there is no 
consensus and no approved treatment for debilitating 
fatigue and motor weakness in GBS patients who have 
not fully recovered, leading to significantly reduced 
functional status and quality of life for many.11,12,13 
Since GBS is rare condition, the evidence on its 
complications is not commonly generated. A review by 
Ahmed SI revealed some observations on GBS over the 
years from Pakistan. The overall incidence ranges 
between 1.7/100000/population to 
3.8/100000/population in the country.14  The primary 
aim of this study was to assess the symptoms and 
Residual weakness and Functional Status of patient 
post therapy, secondly to determine seasonal variation 
of GBS. 
METHODOLOGY:
This retrospective study was carried out at the 
Neurology Department, Pakistan Institute of Medical 
Sciences, Islamabad in a period of 2 years from 1st July 
2018 to 30th June 2020 A total of 45 cases of GBS 
presented during this period whose medical record was 
available for analysis. Administrative permission from 
head of the Department was taken for using the 
medical record and study was approved by the hospital 
ethics committee. 
The diagnosis of GBS was made on the basis of clinical 
signs and symptoms symmetrical and the specific 
laboratory investigations i.e. lumbar puncture for CSF 
investigation to demonstrate cytological-albumin 
dissociation. The subtypes of GBS was classified on the 
basis  electromyography and nerve conduction study 
(axonal motor, axonal motor and sensory or 
demyelinating).  
Patient included in this study was 13 to 60 years, with 
history of less than 4 weeks of progressive, symmetrical 
weakness with areflexia or hyporeflexia. Weakness 
supported with cranial nerve involvement or sensory 
symptoms Patient was recruited during all seasons with 
or without history of preceding illness. Patient who were 
less than 13 and above 60 years of age excluded. 
Patient already diagnosed and taking treatment for 
neuropathy secondary to metabolic disease (Diabetes, 
Hypothyroidism, Chronic kidney disease, Vitamin B12 
deficient, Toxins) were excluded.
The study information included demographic (age, 
gender), clinical (variants, preceding infection, type of 
infection, autonomic dysfunction, ventilator support 
and seasonal presentation), treatment status (type of 
treatment, post treatment symptoms, functional status 
and residual weakness). 
The primary outcome was to quantify the clinical 
presentation of patients with GBS and to see the 
outcome after treatment. Secondly, the seasonal 
variation of GBS was also measured.  
Data was analyzed in SPSS version 20.0. The 
categorical variables like clinical presentation, 
treatment, type of infection and post treatment 
symptoms were measured as frequency and 
percentages. The continuous numerical variables like 
age and disability rating index (residual weakness) were 
measured as mean and standard deviations. 
RESULTS:
There were 45 cases of GBS in this study. The mean 
age of patients was 38.7 years, majority of them were 
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Table 1: Demographic features of study patients (n=45) 
 No. of cases %age 
Age (years)   
   13 to 20 6 13.3% 
   21 to 30 16 35.6% 
   31 to 40 6 13.3% 
   41 to 50 3 6.6% 
   51 to 60 8 17.7% 
   61 or above 6 13.3% 
Mean ± SD 38.7 ± 19.1  
Gender   
   Male 14 31.1% 




below 40 years. Females were predominant, n=31 
(68.9%). Most of the patients had AIDP, n=25 (55.6%) 
and AMAN, n=14 (31.1%) variants. There were 25 
(55.6%) patients with preceding infections; 
gastrointestinal tract and upper respiratory tract 
infection were the infection types. Three (6.6%) 
patients each had autonomic dysfunction and required 
ventilator support. 
The presentation of GBS was assessed according to 
seasonal variation. Most of the patients presented in 
(September, October, November) Autumn, n=18 
(40.0%) and (June, July, August) Summer seasons, 
n=14 (31.1%).  In this study most of the patients were 
treated using PLEX treatment (5, sessions 200-250 ml 
of plasma per Kg weight) n=37 (82%), whereas n=7 
(15.8%) were managed by IV Ig treatment (0.4mg/Kg in 
divided doses). (Figure I) and (Figure II)
Majority of patient was falling in HUGES Grade 3-5 in 
pre-treatment group and at discharge patient 
improvement after immunotherapy. We evaluated the 
condition of patients after 3 months interval post 
therapy. The common symptoms after the treatment 
were fatigue, n-=33 (73.2%), pain, n=25 (55.5%), 
depression, n=17 (37.7%) and muscle wasting, n=16 
(35.5%). The other frequent symptoms were tremors, 
dysaesthesia and ataxia. The majority of the patients 
had improved functional status after the treatment. 
There were 26 (57.7%) patients with minor sign 
symptoms (tremor, dysasthesia, and ataxia). Moreover, 
8 (17.7%) patients were able to walk 5 meters without 
help, whereas 6 (13.3%) patients were able to walk five 
meters only with help and 5 (11.1%) of the patients 
were bedridden, unable to walk. None of the current 
study patients died, albeit 3 (6.6%) required 
mechanical ventilation. The mean disability rating index 
was 50.1 ± 15.4 and ranging from 30 to 60. (Table 3)
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DISCUSSION:
The Guillain-Barre syndrome patients in the current 
study presented with AIDP and AMAN variants and 
majority having preceding infections like upper 
respiratory tract infection and gastrointestinal 
infections. After treatment with intravenous 
Immunoglobulin and Plasma exchange the majority of 
patients recovered and were found with minor signs or 
symptoms and were able to run or walk without help. 
However, few cases were still bedridden and few others 
were not able to move without aid. Fatigue and pain 
were the two most frequent symptoms post therapy. 
The evidence regarding epidemiology and management 
of GBS is common but results on sequel is limited. This 
study was planned keeping in view the local context 
where scientific base on GBS is limited specially, the 
outcome of therapies such as IVIG and Plasma 
exchange. 
As witnessed the variants of GBS were AMAN and 
AMSAN in majority of the current study patients, 
however, AIDP presented as the most frequent. This 
fact has been proven by many previous studies as 
well.15 AMAN and AMSAN are two frequent variants 
characterized by an immune system attack mainly 
focused at the axons rather than Schwann cells and 
myelin.16, 17  Ho et al, revealed that patients could be 
categorized into AIDP (86.3%), AMAN (7.8%), and 
AMSAN (5.9%) according to electrophysiological 
findings of GBS.18   
The findings of the current study are comparable with 
many previous studies on the topic from different parts 
of the world. A previous local study by Yaqoob et al 
reviewed 125 34 cases between 1995 to 2003. The 
investigators reported that male gender was more likely 
to have GBS, however, it occurred in all age groups. 
Before GBS their patients had GI and URTI infections. 
Moreover, their patients were managed with IVIG and 
Plasma exchange and no significant difference in the 
outcome of two treatments was observed.19  In the 
present study though we witnessed more females to be 
affected by GBS, however, age distribution was similar 
to that of Yaqoob et al study. The preceding infections 
were also GI and URTI in the current study. Moreover, in 
the current study we also noticed similar outcome with 
IVIG and plasma exchange.
 
Another local study by Wali M and colleagues compared 
the outcome of Plasmapheresis and Immunoglobulin 
treatment in GBS patients and reported that there is no 
difference in the therapeutic effect of both treatment 
regimens.20 These findings are similar to our results 
where we also witnessed that both plasma exchange or 
IVIG treatment are similar in treating GBS. Other 
investigators have also witnessed that outcome is good 
in almost 80-90% patients with Guillain-Barre 
syndrome (GBS) in terms of motor recovery and 
functional outcome, 21 However, in the long run about 
20% patients still face severe motor disability.22 This 
was comparable to the current results as well, it was 
noticed that around 25% of patients had still poor 
functional ability in terms of walk with aid only and 
bedridden state despite being treated for a long period. 
The patients with severe GBS condition do not fully 
recover with IVIg or plasma exchange, There is scientific 
base suggesting that in critical conditions of GBS the 
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non-responsive patients could be given a second dose 
of IVIg after a gap and recovery is certain.23  However, 
our patient only received treatment from either PLEX or 
IVIG’s. Though immunotherapy could be used in critical 
conditions, they must be opted taking into 
consideration the cost factors and the clinical status 
(staging, complications, and other comorbid 
conditions) of individual patients.24
The current study has many advantages; firstly this was 
a rare data on GBS patients from a large tertiary care 
hospital. Secondly, though retrospective in design the 
study collected detailed information regarding patients 
clinical course, seasonal variation and management 
outcome. 
The limitations of the study lie in its retrospective 
observational design, where lack of control and 
randomization could lead to selection and personal 
bias. Moreover, a large number of patients were found 
without response to therapy, how these patients were 
managed and no data on further intervention was 
available. 
CONCLUSION:
In this study most of the patients presented with AIDP 
and AMAN variants. More than half had history of 
preceding infections of URTI and GI. Most of the 
patients were below 40 years of age and females were 
predominantly effected by GBS. Majority of cases of 
GBS were found in autumn season. The patients were 
managed with IVIg and plasma exchange therapies and 
most of them responded to it. Fatigue and pain were 
the most frequent symptoms after therapy. There were 
almost one fourth cases with no response to therapy 
and these patients were bedridden or unable to walk 
without help.
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